Corporate News: China Jiangzhong and the Pharmaceutical Landscape
China Jiangzhong (600750.SS) finished the 24‑hour trading window on Wednesday, 21 October 2026, unchanged at 0 % relative to the previous close. At the close of the session, the stock was quoted at CNY 23.13 on the Shanghai Stock Exchange. The company’s shares are broadly held, with a circulating supply of approximately 635.6 million shares. This level of liquidity has enabled a market capitalisation of CNY 14.8 billion, while the volume of shares traded in the last 24 hours reached about CNY 161 million.
Since the end of September, China Jiangzhong has experienced a modest increase of 6.05 %. The 200‑day simple moving average sits at CNY 23.98, providing a short‑term benchmark for technical observers. In a broader context, the company’s 52‑week high of CNY 27.83 was recorded on 24 April 2026, whereas the 52‑week low of CNY 21.05 occurred on 6 November 2025. These price levels suggest a relatively tight range and an overall upward trajectory for the stock.
Regulatory Milestone and Product Expansion
A key driver of recent investor enthusiasm stems from China Resources Jiangzhong Pharmaceutical Co., Ltd.—a subsidiary of China Resources Group—receiving a drug registration certificate from the National Medical Products Administration (NMPA). The approval covers the Shaoyao Gancao Decoction Granules, a traditional Chinese medicine (TCM) formulation marketed for the alleviation of spasms, pain, and symptoms associated with yin and blood deficiencies. The certification marks a strategic expansion of the parent company into the growing TCM sector, which is increasingly recognised for its complementary role alongside conventional pharmaceuticals.
The announcement coincided with a modest rise in the parent company’s Hong Kong‑listed shares, signalling investor confidence in the new product launch. While details regarding commercial plans, pricing, or market penetration remain undisclosed, the move aligns with the group’s broader objective to diversify its portfolio and strengthen its domestic market presence. The approval also reflects the tightening regulatory environment for TCM products, underscoring the importance of rigorous quality control and clinical evidence for market entry.
Market‑Wide Context: Peer Performance
In the same 24‑hour window, several peer companies exhibited similar flat trading behaviour:
| Symbol | Current Price | Market Cap | PE Ratio |
|---|---|---|---|
| Ningbo Sanxing Medical Ele (601567.SS) | CNY 12.37 | CNY 17.6 bn | 29.7 |
| Betta L (300558.SZ) | CNY 42.05 | CNY 17.7 bn | 37.47 |
| Zhejiang Publishing & Medi (601921.SS) | CNY 7.88 | CNY 17.6 bn | 13.34 |
| Winner Medical (300888.SZ) | CNY 30.02 | CNY 17.7 bn | 21.43 |
| Bgi Genomics (300676.SZ) | CNY 40.93 | CNY 17.6 bn | — |
Betta L’s announcement of a Phase III trial failure for its vorolanib‑based eye drug, DURAVYU, added volatility to the group’s valuation. The company plans to conduct impairment testing on the vorolanib asset group, which may impact earnings. The news prompted a sharp initial decline in the share price before stabilising later in the day.
In contrast, Bgi Genomics benefited from broader sector gains in artificial‑intelligence and robotics, reflecting a market favouring high‑growth biotech and AI‑driven enterprises. Meanwhile, traditional industrial sectors—including coal, non‑ferrous metals, and shipping—experienced modest declines, highlighting a shift in investor appetite toward technology‑enabled health solutions.
Company Profile
Jiangzhong Pharmaceutical Co., Ltd. is headquartered in Nanchang, China, and specializes in the manufacturing of pharmaceutical products, including Chinese medicine preparations and penicillin derivatives. The company was first listed on the Shanghai Stock Exchange on 29 August 1996, and its shares are widely available to institutional and retail investors. Further information can be found on the company’s official website, www.jzjt.com .
The information presented herein is intended for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions.
